New Psychoactive Substances: A Matter of Time.
NPS
analog
controlled substances
early warning system
toxicity
toxicological analysis.
Journal
Current neuropharmacology
ISSN: 1875-6190
Titre abrégé: Curr Neuropharmacol
Pays: United Arab Emirates
ID NLM: 101157239
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
3
10
2019
pubmed:
3
10
2019
medline:
20
2
2020
Statut:
ppublish
Résumé
In the last few years, a wide range of new psychoactive substances (NPS) have been produced and marketed to elude the controlled substance lists. These molecules enter the traditional illegal and web market with poor knowledge about their toxicity, mechanism of action, metabolism, abuse potential so that they are directly tested by the consumers. This perspective highlights the main issues connected with NPS: the celerity they enter and leave the market once included in the banning laws to be substituted by new legal analogues; the unavailability of analytical screening tests and certified standards to perform toxicological analyses; the time lag between NPS identification and inclusion in the controlled substances lists. Finally, the authors take a snapshot of the commitment of the Italian Early Warning System in highlighting the recent seizures of NPS as well as the distribution of NPS related intoxication and deaths as an example of what is happening in the European countries and internationally.
Identifiants
pubmed: 31577198
pii: CN-EPUB-99998
doi: 10.2174/1570159X1709190729101751
pmc: PMC7052837
doi:
Substances chimiques
Designer Drugs
0
Illicit Drugs
0
Psychotropic Drugs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
818-822Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Références
Curr Neuropharmacol. 2017;15(5):656-657
pubmed: 28000553
Drug Test Anal. 2011 Jul-Aug;3(7-8):483-95
pubmed: 21671427
Drug Test Anal. 2019 Jan;11(1):173-177
pubmed: 30091284
Front Neurosci. 2016 Apr 19;10:153
pubmed: 27147945
Int J Legal Med. 2017 Nov;131(6):1543-1553
pubmed: 28710651
Eur Rev Med Pharmacol Sci. 2018 Jan;22(1):268-274
pubmed: 29364498
Curr Top Behav Neurosci. 2017;32:209-230
pubmed: 27753008
Front Pharmacol. 2017 Oct 31;8:785
pubmed: 29163170
Eur Rev Med Pharmacol Sci. 2015 Oct;19(19):3777-90
pubmed: 26502870
Handb Exp Pharmacol. 2018;252:113-142
pubmed: 30406443
Curr Neuropharmacol. 2015 Jan;13(1):26-46
pubmed: 26074742
Biochem Pharmacol. 2008 Jan 1;75(1):17-33
pubmed: 17977517
Curr Neuropharmacol. 2017;15(5):738-749
pubmed: 27908258
Front Pharmacol. 2018 Jul 10;9:747
pubmed: 30042684
Front Pharmacol. 2018 Jun 20;9:654
pubmed: 29973882
Ther Drug Monit. 2018 Feb;40(1):38-51
pubmed: 29120973
Forensic Sci Int. 2017 Apr;273:e10-e14
pubmed: 28190538
Toxicol Lett. 2019 May 1;305:73-80
pubmed: 30682400
J Med Toxicol. 2012 Mar;8(1):15-32
pubmed: 22271566
Pharmacol Ther. 2018 Feb;182:193-224
pubmed: 29097307
J Pharm Biomed Anal. 2019 Jan 30;163:170-179
pubmed: 30316062